| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1977) |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| ATC: | C10AX02 |
| UNII: | P3CTH044XJ |
| InChI Key | FYPMFJGVHOHGLL-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C31H48O2S2 |
| Molecular Weight | 516.86 |
| AlogP | 9.91 |
| Hydrogen Bond Acceptor | 4.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 4.0 |
| Polar Surface Area | 40.46 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 35.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | ATP-binding cassette sub-family A member 1 inhibitor | PubMed |
| Primary Target | |
|---|---|
| ABCA1 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Oxidoreductase
|
- | 14000 | - | - | 27-37 | |
|
Enzyme
Transferase
|
- | - | - | - | 29 | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class III
|
- | 1600 | - | - | - | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 102 |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Hyperlipidemias | 3 | D006949 | ClinicalTrials |
| Diabetic Nephropathies | 2 | D003928 | ClinicalTrials |
| Peripheral Arterial Disease | 2 | D058729 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 23288-49-5 |
| ChEBI | 8427 |
| ChEMBL | CHEMBL608 |
| DrugBank | DB01599 |
| DrugCentral | 2269 |
| EPA CompTox | DTXSID2045440 |
| FDA SRS | P3CTH044XJ |
| Human Metabolome Database | HMDB0015537 |
| Guide to Pharmacology | 7277 |
| KEGG | C07373 |
| PharmGKB | PA451107 |
| PubChem | 4912 |
| SureChEMBL | SCHEMBL4150 |
| ZINC | ZINC000001530755 |